Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | TDO2 | P48775 | 2/20 | 0.36 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31264458 | 0.85 | CHRM1 (0.50) | MEN1KMT2ANPSR1CYP1A2CYP2D6 | |
| SCHEMBL553741 | 0.85 | CHRM1 (0.50) | MEN1KMT2ANPSR1CYP1A2CYP2D6 | |
| SCHEMBL553920 | 0.85 | CHRM1 (0.50) | MEN1KMT2ANPSR1CYP1A2CYP2D6 | |
| SCHEMBL553740 | 0.85 | CHRM1 (0.50) | MEN1KMT2ANPSR1CYP1A2CYP2D6 | |
| SCHEMBL31451120 | 0.85 | CHRM1 (0.50) | MEN1KMT2ANPSR1CYP1A2CYP2D6 | |
| SCHEMBL570573 | 0.80 | MGLL (0.43) | MEN1KMT2AMAPTHSD11B1IDO1 | |
| SCHEMBL10175161 | 0.79 | AKT1 (0.35) | CYP1A2MAPTPTGDR2NR1H4AKT1 | |
| SCHEMBL9940818 | 0.77 | ADRB2 (0.45) | MEN1KMT2ANPSR1CYP2D6IDO1 | |
| SCHEMBL16423035 | 0.76 | AKT1 (0.51) | NPSR1CYP2C19PTGDR2AKT1IDO1 | |
| SCHEMBL29609167 | 0.75 | ADRB2 (0.46) | CYP2D6IDO1TDO2CNR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160176906-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-06-23 | — | — | US | disclosed |
| US-9248140-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2016-02-02 | — | — | US | disclosed |
| US-20150328239-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2015-11-19 | — | — | US | disclosed |
| US-9018381-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-04-28 | — | — | US | disclosed |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (UK) | 2013-11-21 | — | — | US | disclosed |
| US-20120035134-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035134-A1 | CHEMICAL COMPOUNDS | BCL2, BCL2L1, BAX | MEN1 2368/4885KMT2A 2562/4885NPSR1 3981/4885 |
| US-20150328239-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | MEN1 2368/4885KMT2A 2562/4885NPSR1 3981/4885 |
| US-20160176906-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | MEN1 2368/4885KMT2A 2562/4885NPSR1 3981/4885 |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | BCL2, BAX, BCLAF1 | MEN1 4724/4885KMT2A 1548/4885NPSR1 3714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.